The latest financing involved the exercise of milestone-based callable warrants held by existing investors in Knopp. The company anticipates making a further series B call of $10 million following the initiation of Phase II studies of KNS-760704 in amyotrophic lateral sclerosis.
Saturn Capital of Boston acted as exclusive placement agent for Knopp’s series A and series B financings.